Komori
Stella Pharma (4888) · InitiativeAchieved

Reduction of Stated Capital and Capital Reserve and Transfer of Surplus to Cover the Accumulated Deficit

First written in FY2022. 4 of 6 entries say "Achieved", first in FY2023-Q1. Latest entry: FY2026-H1.

6entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAchievedFY2023-Q1 – FY2026-H12022: 220222023: 120232024: 120242025: 22025
Same theme, other companies
Capital Policy and Dividend Preparation Through Capital Reduction and Deficit CoverageA theme 287 companies write about · 1 as a headwind · 286 as a tailwind

127 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 289 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1AchievedAnnual report

    「As a result of the reduction of capital surplus and the disposition of retained earnings on 1 July 2025, capital surplus decreased by ¥140.811 million and retained earnings increased by ¥140.811 million.」

    The reduction of capital surplus and transfer to retained earnings were implemented on 1 July 2025, completing the capital policy relating to the elimination of accumulated deficits.
  2. FY2025AdvancedAnnual report

    「At a meeting of the Board of Directors held on 21 May 2025, the Company resolved to reduce the capital reserve and dispose of other capital surplus, including the elimination of the deficit in retained earnings brought forward, with 1 July 2025 as the effective date. The Company plans to reduce the capital reserve by ¥140.811 million and transfer other capital surplus to retained earnings brought forward to eliminate the deficit.」

    Resolved to eliminate the deficit through a ¥140.811 million reduction in the capital reserve and a transfer from surplus, effective 1 July 2025.
  3. FY2025-H1AchievedAnnual report

    「As a result of the reduction of share capital and the capital reserve and the disposition of surplus on 2 August 2024, share capital decreased by ¥568.027 million, the capital reserve decreased by ¥195.722 million, and retained earnings brought forward increased by ¥763.749 million.」

    States that reductions in share capital and the capital reserve and the disposition of surplus were implemented on 2 August 2024 to eliminate accumulated deficits.
  4. FY2024-Q1AchievedAnnual report

    「At a meeting of the Board of Directors held on 22 May 2023, the Company resolved to submit a proposal concerning reductions in share capital and the capital reserve and the disposition of surplus to the 16th Annual General Meeting of Shareholders held on 27 June 2023. The proposal was approved at that meeting and became effective on 1 August 2023. The purpose is to eliminate accumulated deficits and ensure flexibility and agility in future capital policies.」

    A capital policy involving reductions of ¥558.029 million in share capital and ¥220.794 million in the capital reserve and a transfer of ¥778.824 million of other capital surplus to retained earnings brought forward was approved and became effective on 1 August 2023.
  5. FY2023-Q1AchievedAnnual report

    「At a meeting of the Board of Directors held on 26 May 2022, the Company resolved to submit a proposal concerning reductions in share capital and the capital reserve and the disposition of surplus to the 15th Annual General Meeting of Shareholders held on 29 June 2022. The proposal was approved at that meeting and became effective on 2 August 2022.」

    Reductions in share capital and the capital reserve and the disposition of surplus, intended to eliminate accumulated deficits and ensure flexibility and agility in capital policy, were approved at the general meeting of shareholders and became effective on 2 August 2022.
  6. FY2022First statedAnnual report

    「The purpose is to eliminate accumulated deficits and ensure flexibility and agility in future capital policies. Subject to the effectiveness of the reductions in share capital and the capital reserve, other capital surplus will be transferred to retained earnings brought forward and applied to eliminate the deficit.」

    The Company describes a plan, effective 2 August 2022, to reduce share capital by ¥728,653,376 and the capital reserve by ¥1,908,276,800, and transfer ¥2,636,930,176 of other capital surplus to retained earnings brought forward.
Moved together

"Global Expansion Through U.S. and European Regulatory Approvals and Partnerships" moved the same way as this thread, in the same document, in 4 of its 6 moves.

444333★123456
  1. ★This thread
  2. 1Global Expansion Through U.S. and European Regulatory Approvals and Partnerships4×
  3. 2Strategy to expand the domestic indications for Steboronin4×
  4. 3Phase I clinical trial for malignant melanoma and angiosarcoma4×
  5. 4Phase II clinical trial for recurrent high-grade meningioma3×
  6. 5Development of a technology for determining eligibility for boron neutron capture therapy (BNCT) using 18F-FBPA PET3×
  7. 6Raising awareness of BNCT and expanding accelerator adoption3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Stella Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.